Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: arnie h who wrote (990)	2/9/2000 4:26:00 AM
From: Jesse Schulman	Read Replies (2) \| Respond to of 1386

Arnie - My reading of Reuter's was Aviv meant only that the EASDAQ listing wouldn't in itself be dilutive. Not sure how it works anyway - guess it becomes just another outlet to buy and sell the stock. The write-through I saw didn't have the phase 2 stuff in quotes, and sounded to me like a re-hash of what we already know. Journalistic condensation is rarely so precise as to stand up to parsing. The 1m-share sell did seem to come right out of the blue and wasn't exactly what the company had been leading people to expect. Prior to that they'd been talking about getting the P2/3 bucks by hocking part of the future revenue stream. My guess is that deal is still sitting out there somewhere, just out of reach. It seems clear though that the enormous improvement in the biotech investment climate works in PARS's favor. With crossed fingers, itss